Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Setback For Roche As Delhi Court Dismisses Patent Claims On Tarceva; Cipla Allowed To Market Copies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A sensational fight that lasted more than a year between Roche and India's Cipla over the patentability of anti-cancer drug Tarceva (erlotinib) ended in a defeat for the Swiss drug maker as the Delhi High Court in a landmark decision dismissed its patent claims

You may also be interested in...



Roche Says Product Launches, Investments Go Unabated In India Irrespective Of Patent Controversies; Speaks Out On Patient Access Programs

MUMBAI - Battling controversial patent litigations has neither deterred Swiss drug maker Roche from introducing new drugs in the Indian market nor has the company held back investments for growth in the country in fear of debatable intellectual property issues. That direct message was sent across by Roche India's Managing Director Girish Telang as he stressed hard to prove that his company had not exorbitantly priced a range of life saving drugs

Roche Says Product Launches, Investments Go Unabated In India Irrespective Of Patent Controversies; Speaks Out On Patient Access Programs

MUMBAI - Battling controversial patent litigations has neither deterred Swiss drug maker Roche from introducing new drugs in the Indian market nor has the company held back investments for growth in the country in fear of debatable intellectual property issues. That direct message was sent across by Roche India's Managing Director Girish Telang as he stressed hard to prove that his company had not exorbitantly priced a range of life saving drugs

Cipla Questions Patentability Of Roche’s Tarceva In Ongoing Dispute

MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel